Advertisement

ST-Segment Elevation Myocardial Infarction (Lytic Candidate) on Oral Anticoagulant

  • Craig J. Beavers
Chapter

Abstract

Patients on oral anticoagulation who present with a ST-segment myocardial infarction and require fibrinolytics therapy represent a high patient population. With limited evidence to guide management, providers must assess risk versus benefit and attempt to mitigate bleeding events.

Keywords

Fibrinolytics STEMI Bleeding Door-to-needle Risk assessment Hemorrhage 

References

  1. 1.
    O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61(4):e78–e140.CrossRefPubMedGoogle Scholar
  2. 2.
    Lip GYH, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Intervention (EAPCI), and the European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155–79.CrossRefPubMedGoogle Scholar
  3. 3.
    Sarrinen S, Puolakka J, Boyd J, et al. Warfarin and fibrinolysis-a challenging combination: an observational cohort study. Scand J Trauma Resusc Emerg Med. 2011;19:21.CrossRefGoogle Scholar
  4. 4.
    Bovill E, Terrin M, Stump D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infraction (TIMI) phase II trial. Ann Intern Med. 1991;115(4):256–65.CrossRefPubMedGoogle Scholar
  5. 5.
    Stanley AG, Fletcher S, Tan A, Barnett DB. Is warfarin a contraindication to thrombolysis in acute ST elevation myocardial infarction? Heart. 2006;92(8):1145–6.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Brass L, Lichtman J, Wang Y, et al. Intracranial haemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the cooperative cardiovascular project. Stroke. 2000;31:1802–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47:581–641.CrossRefPubMedGoogle Scholar
  8. 8.
    Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J. 2012;33(10):1232–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Cardiovascular Clinical Pharmacy Cooridnator, University of Kentucky Healthcare, Department of Pharmacy Practice and ScienceUniversity of Kentucky, College of PharmacyLexingtonUSA

Personalised recommendations